|Bid||105.15 x 6700|
|Ask||105.20 x 11200|
|Day's Range||104.20 - 105.70|
|52 Week Range||85.84 - 105.85|
|Beta (3Y Monthly)||0.33|
|PE Ratio (TTM)||13.24|
|Earnings Date||Nov 14, 2019|
|Forward Dividend & Yield||1.25 (1.20%)|
|1y Target Est||N/A|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of MERCK...
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Merck KGaA and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Merck KGaA ("Merck") announced that its transaction with Versum Materials, Inc ("Versum") had been approved at a special meeting among Versum's shareholders. Merck had signed a definitive agreement to acquire Versum for a consideration of $53 in cash in April this year, notes Moody's.
Could MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) be an attractive dividend share to own for the long haul...
FRANKFURT (Reuters) - Germany's Merck KGaA, which is taking over U.S. electronic chemicals maker Versum Materials, said it expected a slight tailwind from foreign exchange effects supporting earnings growth ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to examine MERCK Kommanditgesells...
European shares slid on Tuesday, with most sectors falling after the United States threatened to slap tariffs on goods from the European Union, with worries compounded by the IMF cutting its global growth forecast. The U.S. Trade Representative proposed a list of European Union products late on Monday on which to slap tariffs in retaliation to more than $11 billion of EU subsidies to Airbus the World Trade Organization has found cause "adverse effects" to the United States.
The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.
Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.
Announcement: Moody's says revised proposal from Merck KGaA is credit positive for Versum. Global Credit Research- 09 Apr 2019. New York, April 09, 2019-- Moody's Investors Service commented on the announcement ...
Versum Materials, Inc . (NYSE: VSM ) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27. ...
Merck KGaA won the backing of Versum's board for a sweetened $6.5 billion takeover proposal, overturning an agreed merger with rival Entegris as it bets on a recovery in electronic materials markets. "This proposal constitutes a 'Superior Proposal' as defined in Versum's previously announced merger agreement with Entegris, Inc.," Versum said in a statement on Monday. On a per share basis, Germany's Merck offered $53, up from $48 previously, after reviewing business data and following meetings between Merck Chief Executive Stefan Oschmann and Versum Chairman Seifi Ghasemi, filings showed.